臨床研究等提出・公開システム

Date of registration	Aug. 27, 2013
Last modified on	May. 16, 2022
Trial ID	jRCT2080222202

Scientific Title	-
Public Title	-

Completion Date or Terminated date	Feb. 28, 2020
Actual Enrolled Number
Baseline Characteristics
Participant flow
Adverse events
Primary Outcome Measures
Secondary Outcome Measures
Brief summary
Posting of journal publication
Date of the first journal publication of results
URL hyperlink(s) related to results and publications

Plan to share IPD	Yes
Plan description	-
URL link to protocol file(s)
Version of protocol file(s)	version: date:

Contact for Scientific Queries	Name
	Contact Name for Scientific Queries
	Address
	Phone Number	-
	E-mail Address	JPCT@msd.com

Contact for Public Queries	Name
	Contact Name for Public Queries
	Address
	Phone Number	-
	E-mail Address	JPCT@msd.com

Recruitment Status	completed

Date of First Enrolment		April. 26, 2013
Target Sample Size		84
Study Type		Interventional
Study Design	Study Design
Study Design	Objective	treatment purpose
Phase		1
Key inclusion & exclusion criteria	Inclusion Criteria
	Exclusion Criteria
	Minimum Age	20age old over
	Maximum Age	No limit
	Gender	Both
Health Condition or Problem Studied
Intervention(s)		investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Cisplatin,Pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Carboplatin,Pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Carboplatin,Pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Carboplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Ipilimumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Cisplatin,Etoposide Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Carboplatin,Etoposide Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pembrolizumab,Carboplatin,Etoposide,Pegfilgrastim Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material :
Health Condition(s) Keyword
Intervention(s) Keyword
Health Condition(s) Code
Intervention(s) Code
Primary Outcome		safety
Secondary Outcome

Primary Sponsor	-
Secondary Sponsor	-

Name of Funding Organization
Name of Research Funding

Name of IRB
Address of IRB
Phone Number of IRB	2018/3/26通知発出前に治験届提出の試験（古い試験のため、IRBの掲載許可なし）
E-mail Address of IRB	-
Status of IRB Review	approved
Date of Approval by IRB	Mar. 26, 2013

Secondary ID No.	NCT01840579
Name of Other Registries	ClinicalTrials.gov

Secondary ID No.	JapicCTI-132249
Name of Other Registries

Countries / Regions of Recruitment	Japan

History of Changes

No	Publication date
8	May. 16, 2022	(this page)	Changes
7	May. 22, 2018	Detail	Changes
6	Feb. 01, 2018	Detail	Changes
5	Nov. 29, 2016	Detail	Changes
4	Feb. 02, 2016	Detail	Changes
3	July. 03, 2015	Detail	Changes
2	June. 16, 2014	Detail	Changes
1	Aug. 27, 2013	Detail

List of change history